Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
B4GalT1 Antibody (C-term) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
| Primary Accession | P15291 |
|---|---|
| Clone Names | 90713269 |
| Gene ID | 2683 |
|---|---|
| Other Names | Beta-1, 4-galactosyltransferase 1, Beta-1, 4-GalTase 1, Beta4Gal-T1, b4Gal-T1, 241-, UDP-Gal:beta-GlcNAc beta-1, 4-galactosyltransferase 1, UDP-galactose:beta-N-acetylglucosamine beta-1, 4-galactosyltransferase 1, Lactose synthase A protein, N-acetyllactosamine synthase, Nal synthase, Beta-N-acetylglucosaminylglycopeptide beta-1, 4-galactosyltransferase, Beta-N-acetylglucosaminyl-glycolipid beta-1, 4-galactosyltransferase, 241-, Processed beta-1, 4-galactosyltransferase 1, B4GALT1, GGTB2 |
| Target/Specificity | The synthetic peptide sequence used to generate the antibody AP8892b was selected from the C-term region of human B4GalT1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. |
| Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
| Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
| Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
| Name | B4GALT1 (HGNC:924) |
|---|---|
| Synonyms | GGTB2 |
| Function | [Beta-1,4-galactosyltransferase 1]: The Golgi complex form catalyzes the production of lactose in the lactating mammary gland and could also be responsible for the synthesis of complex-type N-linked oligosaccharides in many glycoproteins as well as the carbohydrate moieties of glycolipids. |
| Cellular Location | [Isoform Long]: Golgi apparatus, Golgi stack membrane; Single-pass type II membrane protein. Cell membrane; Single-pass type II membrane protein Cell surface. Cell projection, filopodium {ECO:0000250|UniProtKB:P15535}. Note=Found in trans cisternae of Golgi but is mainly localized at the plasma membrane (PubMed:1714903) B4GALT1 cell surface expression is regulated by UBE2Q1 (By similarity) {ECO:0000250|UniProtKB:P15535, ECO:0000269|PubMed:1714903} [Processed beta-1,4-galactosyltransferase 1]: Secreted. Note=Soluble form found in body fluids. |
| Tissue Location | Ubiquitously expressed, but at very low levels in fetal and adult brain |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
B4GalT1 is an enzyme that participates both in glycoconjugate and lactose biosynthesis. For the first activity, the enzyme adds galactose to N-acetylglucosamine residues that are either monosaccharides or the nonreducing ends of glycoprotein carbohydrate chains. The second activity is restricted to lactating mammary tissues where the enzyme forms a heterodimer with alpha-lactalbumin to catalyze UDP-galactose + D-glucose <=> UDP + lactose. The two enzymatic forms result from alternate transcription initiation sites and post-translational processing.
References
Mengle-Gaw,L., et.al., Biochem. Biophys. Res. Commun. 176 (3), 1269-1276 (1991)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
